Negative
●
Invezz
●
about one month ago
Moderna stock (NASDAQ: MRNA) rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking funds. The move follows a spectacular 2026 rally that has pushed Moderna more than 500% higher and transformed it from a post-pandemic recovery story into an oncology bet.